- RecruitingPHASE3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
This study looks at a new medicine called felzartamab for adults with a kidney disease called IgA nephropathy (IgAN). Researchers want to see if it reduces protein in the urine and helps kidney function. It involves infusions and careful monitoring.
For: Immunoglobulin A Nephropathy (IgAN)United States · Argentina · Australia - RecruitingPHASE3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
This study looks at a new drug, felzartamab, for Primary Membranous Nephropathy (PMN), a kidney disease. Researchers compare it to an existing treatment, tacrolimus, to see how well it works in reducing protein in urine and improving kidney health.
For: Primary Membranous NephropathyUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
This study is looking into a new medicine called felzartamab for people with lupus nephritis (LN), a kidney problem caused by lupus. Researchers want to see if it's safe and how it works to help reduce kidney damage, alongside usual treatments.
For: Lupus NephritisUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
This study looks at a new drug, felzartamab, for adults who've had a kidney transplant and then developed a problem called 'isolated microvascular inflammation' (MVI). MVI is when tiny blood vessels in the transplanted kidney get inflamed, which can cause serious issues. We want to see if felzartamab can help reduce this inflammation.
For: Microvascular InflammationUnited States · Austria · Brazil - Active not recruitingPHASE3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
This study looks at a new drug, felzartamab, for adults with kidney transplants experiencing antibody-mediated rejection (AMR). AMR is when the body's immune system attacks the new kidney. Researchers want to see if felzartamab can help the kidney recover and reduce damage.
For: Antibody-mediated RejectionUnited States · Argentina · Australia